Redx Pharma Human Tissue NRES application v2020
Research type
Research Study
Full title
The use of primary human cells for drug discovery
IRAS ID
290409
Contact name
Caroline Phillips
Contact email
Sponsor organisation
Redx Pharma
Duration of Study in the UK
5 years, 0 months, 2 days
Research summary
Redx Pharma Plc, is a pharmaceutical company based in Cheshire, England, developing new drug candidates for various autoimmune diseases, fibrosis diseases and oncology. Redx Pharma aims to discover novel compounds to develop into targeted treatments in these therapeutic areas.
Compounds will be screened in various biochemical, enzymatic and cell based assays. Cell based assays developed by Redx Pharma aim to model the mode of action of a target in its disease setting and in some cases in a physiological setting, as closely as possible. This allows a robust understanding of the efficacy and safety of the proposed target and the activity of drugs in development. In some cases this can be achieved using characterised mammalian cell lines, however for some drug targets, cell lines do not represent the functional characteristics of the compound’s target cells. Redx Pharma is therefore proposing to isolate primary cells from anonymised human blood or tissue. Samples will be taken from healthy volunteers or patient populations and used for functional assays and toxicity screening of drug candidates.
Primary cells and tissue may also be used for method development for experiments intended to asses patient response or patient selection biomarkers for Redx Pharma clinical trials of drug candidates.REC name
London - Surrey Borders Research Ethics Committee
REC reference
20/PR/0935
Date of REC Opinion
18 Jan 2021
REC opinion
Favourable Opinion